China Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024

MT NewswiresJan 22 17:57

CHINARES PHARMA (03320.HK): China Resources Boya Bio-pharmaceutical Group's Net income for 2024 is expected to be between 0.38 billion and 0.48 billion yuan.

Glory Financial reported on January 22 that CHINARES PHARMA (03320.HK) announced that on January 22, 2025, China Resources Boya Bio-pharmaceutical Group will publish its performance forecast for the year ending December 31, 2024. According to this announcement, the net income attributable to the shareholders of China Resources Boya Bio-pharmaceutical Group for the year ending December 31, 2024, is expected to be between approximately RMB 380 million and RMB 480 million (compared to approximately RMB 237.46 million in net income for the same period last year), while the net income attributable to the shareholders of China Resources Boya Bio-pharmaceutical Group after deducting non-recurring gains and losses is expected to be between approximately RMB 283.74 million and RMB.

Gelonghui FinanceJan 22 16:55

Express News | China Resources Boya Bio-pharmaceutical Group: It is expected that the net income in 2024 will grow by 60.03%–102.14% compared to the previous year.

BreakingsJan 22 16:25

Liberal Arts Biotech: 2024 Annual Results Forecast

SZSIJan 22 16:22 · Announcements

Express News | Today, a total of 39 stocks on the A-share market experienced block trades, with Hengyi Petrochemical, Xinxiangwei, and Zhongjin Gold Corp., Ltd. having the highest transaction volumes.

BreakingsJan 13 17:42

Express News | This week, 30 listed companies announced the disclosure of share repurchase and related situations regarding renewed loans. TIGERMED repurchased with loans not exceeding 0.7 billion yuan.

BreakingsJan 12 19:38